TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Up 13.9% – Should You Buy?

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)’s share price shot up 13.9% during trading on Friday . The stock traded as high as $1.64 and last traded at $1.64. 1,587 shares traded hands during trading, a decline of 80% from the average session volume of 7,977 shares. The stock had previously closed at $1.44.

TriSalus Life Sciences Stock Up 13.9%

The stock’s 50 day moving average is $1.28 and its two-hundred day moving average is $1.52.

Hedge Funds Weigh In On TriSalus Life Sciences

A hedge fund recently raised its stake in TriSalus Life Sciences stock. Citadel Advisors LLC increased its holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) by 439.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 126,876 shares of the company’s stock after buying an additional 103,336 shares during the period. Citadel Advisors LLC’s holdings in TriSalus Life Sciences were worth $199,000 as of its most recent filing with the Securities & Exchange Commission.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.